Leadiant Biosciences
As of the edition of 20 October 2026, Leadiant Biosciences runs 8 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Amphotericin b | none listed | 0 |
| Procarbazine | none listed | 0 |
| Cysteamine | none listed | 0 |
| Levocarnitine | none listed | 0 |
| Chenodiol | none listed | 1 |
| Elapegademase | Ends 2030 (computed from the first US licence) | 0 |
| Pegademase bovine | Ended 2002 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| NR1H4 Bile acid receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Leadiant Biosciences needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 1 trials led
- Immune system: 1 trials led
- Inherited and neonatal: 1 trials led